Table 1.
|
1 yr survivor patients, (n = 113)
|
1 yr non-survivor patients, (n = 14)
|
P
value
|
Serum sFasL (pg/mL) - median (p 25-75) | 85 (44-382) | 477 (269-496) | < 0.001 |
Age of liver donor (yr) - median (p 25-75) | 52 (35-64) | 62 (49-73) | 0.049 |
Age of liver recipient (yr) - median (p 25-75) | 59 (52-62) | 56 (53-62) | 0.88 |
Serum alpha-fetoprotein (ng/dL) - median (p 25-75) | 8 (4-37) | 13 (5-180) | 0.36 |
MELD score - median (p 25-75) | 15 (12-18) | 16 (14-18) | 0.78 |
Nodules size (cm) - median (p 25-75) | 3.0 (2.0-3.5) | 2.8 (1.6-4.3) | 0.94 |
Protein (g/dL) - median (p 25-75) | 6.7 (6.0-7.1) | 6.7 (5.7-7.7) | 0.83 |
Leukocytes (count/mm3) - median (p 25-75) | 4800 (3590-6200) | 4940 (3490-7920) | 0.60 |
Albumin (g/dL) - median (p 25-75) | 3.3 (2.9-4.1) | 3.3 (2.9-4.2) | 0.91 |
Creatinine (mg/dL) - median (p 25-75) | 0.9 (0.8-1.1) | 1.0 (0.8-1.1) | 0.43 |
BMI (kg/m2) - median (p 25-75) | 27.6 (24.5-30.0) | 28.1 (23.1-31.1) | 0.80 |
Gender female - n (%) | 18 (15.9) | 0 | 0.11 |
Portal hypertension - n (%) | 77 (68.1) | 10 (71.4) | 0.80 |
Child-Pugh score - n (%) | 0.47 | ||
A | 53 (46.9) | 9 (64.3) | |
B | 34 (30.1) | 3 (21.4) | |
C | 26 (23.0) | 2 (14.3) | |
Multinodular tumor- n (%) | 33 (29.2) | 5 (35.7) | 0.62 |
Macrovascular invasion - n (%) | 7 (6.2) | 0 | 0.34 |
Microvascular invasion - n (%) | 26 (23.0) | 3 (21.4) | 0.89 |
Infiltration - n (%) | 38 (33.6) | 3 (21.4) | 0.36 |
Inside Milan criteria previously to LT - n (%) | 108 (95.6) | 13 (92.9) | 0.65 |
Inside Milan criteria after LT - n (%) | 97 (85.8) | 10 (71.4) | 0.16 |
Treatment previously to LT - n (%) | 62 (54.9) | 10 (71.4) | 0.24 |
Transplantation technique – n (%) | 0.63 | ||
By-pass | 41 (36.3) | 6 (42.9) | |
Piggy back | 72 (63.7) | 8 (57.1) | |
Degree of tumor differentiation – n (%) | 0.51 | ||
Well | 83 (73.5) | 11 (78.6) | |
Moderate | 27 (23.9) | 2 (14.3) | |
Poor | 3 (2.7) | 1 (7.1) |
MELD: Model for end-stage liver disease; BMI: Body mass index; sFasL: Soluble FasL.